Research programme: complement system protein inhibitors - BMS

Drug Profile

Research programme: complement system protein inhibitors - BMS

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator iPierian
  • Developer Bristol-Myers Squibb; iPierian
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Cardiovascular disorders; Immunological disorders; Metabolic disorders; Neurodegenerative disorders

Most Recent Events

  • 08 Dec 2015 Discontinued - Preclinical for Immunological disorders in USA (Parenteral)
  • 08 Dec 2015 Discontinued - Preclinical for Autoimmune haemolytic anaemia in USA (Parenteral)
  • 29 Apr 2014 iPierian has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top